How a gut hormone became a blockbuster peptide drug: the science behind GLP-1

What the study found

In the STEP 1 randomized phase 3 trial (New England Journal of Medicine, 2021), adults with overweight or obesity who received once-weekly semaglutide 2.4 mg lost substantially more weight than those on placebo, alongside lifestyle counseling. Semaglutide is a GLP-1 receptor agonist — an engineered version of a natural peptide. This describes what the trial measured; it is not advice, and nothing here is a recommendation to use any medicine.

The peptide-engineering story

GLP-1 (glucagon-like peptide-1) is an incretin hormone the gut releases after eating; it signals satiety and helps regulate blood sugar. Native GLP-1 is a small peptide that the enzyme DPP-4 degrades within minutes — useless as a drug on its own. The engineering move is to modify the peptide (amino-acid substitutions plus a fatty-acid chain that binds albumin) so it resists degradation and circulates for days, which is what makes weekly dosing possible.

Analysis — the pattern we're watching

Zooming out (this is analysis, not established fact): GLP-1 illustrates a general peptide-therapeutic pattern — take a short-lived endogenous signaling peptide and stabilize it into a durable medicine. The same playbook is now being pushed toward multi-receptor peptides, for example combining GLP-1 with GIP or glucagon activity — an active and still-maturing research direction rather than a settled result. The broader signal is that peptides, long dismissed as too fragile to be drugs, are becoming a major modality.

What's still uncertain

Trials report averages, not individual outcomes. GLP-1 agonists commonly cause gastrointestinal side effects, weight tends to return after the medicine is stopped, long-term safety continues to be studied, and response varies from person to person.